BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Song Y, Cai M, Li Y, Liu S. The focus clinical research in intrahepatic cholangiocarcinoma. Eur J Med Res 2022;27:116. [PMID: 35820926 DOI: 10.1186/s40001-022-00741-9] [Reference Citation Analysis]
2 Hamidi-sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E. Oncolytic viruses and pancreatic cancer. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100563] [Reference Citation Analysis]
3 You W, Ke J, Chen Y, Cai Z, Huang ZP, Hu P, Wu X. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma. Front Immunol 2022;13:864244. [PMID: 35720314 DOI: 10.3389/fimmu.2022.864244] [Reference Citation Analysis]
4 Duan Z, Zhang Y, Tang Y, Gao R, Bao J, Liang B. Adjuvant therapy for periampullary carcinoma and the significance of histopathological typing: A systematic review. Transl Oncol 2022;20:101414. [PMID: 35397420 DOI: 10.1016/j.tranon.2022.101414] [Reference Citation Analysis]
5 Tan X, Bednarsch J, Rosin M, Appinger S, Liu D, Wiltberger G, Garcia Vallejo J, Lang SA, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, De Vos-Geelen J, Valkenburg-van Iersel L, Clahsen-van Groningen MC, de Jong EJM, Groot Koerkamp B, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann UP, Heij LR. PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2190. [PMID: 35565318 DOI: 10.3390/cancers14092190] [Reference Citation Analysis]
6 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
7 Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J, Schmelzle M, Schöning W. Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 2022;14:362. [PMID: 35053523 DOI: 10.3390/cancers14020362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Kunprom W, Aphivatanasiri C, Sa-Ngiamwibool P, Sangkhamanon S, Intarawichian P, Bamrungkit W, Thanee M, Prajumwongs P, Loilome W, Khuntikeo N, Titapun A, Jareanrat A, Thanasukarn V, Srisuk T, Luvira V, Eurboonyanun K, Promsorn J, Koonmee S. Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand. Front Public Health 2022;10:816028. [PMID: 35651852 DOI: 10.3389/fpubh.2022.816028] [Reference Citation Analysis]
9 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Luo R, Li Y, Wu Z, Zhang Y, Luo J, Yang K, Qin X, Wang H, Huang R, Wang H, Luo H. Comprehensive Analysis of Microsatellite-Related Transcriptomic Signature and Identify Its Clinical Value in Colon Cancer. Front Surg 2022;9:871823. [DOI: 10.3389/fsurg.2022.871823] [Reference Citation Analysis]
11 Li H, Chen L, Zhu GY, Yao X, Dong R, Guo JH. Interventional Treatment for Cholangiocarcinoma. Front Oncol 2021;11:671327. [PMID: 34268114 DOI: 10.3389/fonc.2021.671327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xing L, Zhuo L, Wang J, Zhang Y, Zhu F, Wang C, Yin X, Gao B. Values of MRI Imaging Presentations in the Hepatobiliary Phase, DWI and T2WI Sequences in Predicting Pathological Grades of Intrahepatic Mass-Forming Cholangiocarcinoma. Front Oncol 2022;12:867702. [DOI: 10.3389/fonc.2022.867702] [Reference Citation Analysis]
13 Khosla D, Zaheer S, Gupta R, Madan R, Goyal S, Kumar N, Kapoor R. Role of intraluminal brachytherapy in palliation of biliary obstruction in cholangiocarcinoma: A brief review. World J Gastrointest Endosc 2022; 14(3): 106-112 [DOI: 10.4253/wjge.v14.i3.106] [Reference Citation Analysis]
14 Guo L, Zhang J, Liu X, Liu H, Zhang Y, Liu J. Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OTT 2022;Volume 15:629-36. [DOI: 10.2147/ott.s346635] [Reference Citation Analysis]
15 Rizzo A, Brandi G. Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina (Kaunas) 2021;57:212. [PMID: 33652960 DOI: 10.3390/medicina57030212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Satyananda V, Chouliaras K, Cherkassky L, Schwarz RE. A case from the future of HPB surgical oncology: resection of biliary tract cancer after immunotherapy. J Surg Case Rep 2021;2021:rjab414. [PMID: 34729163 DOI: 10.1093/jscr/rjab414] [Reference Citation Analysis]
17 Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2022;14:1748. [PMID: 35406520 DOI: 10.3390/cancers14071748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xing L, Zhuo L, Zhang Y, Ma X, Ma Z, Zhao Y, Yin X, Gao B. DWI Combined With Hepatobiliary-Phase Enhanced Imaging Can Better Differentiate Cholangiocarcinoma From Atypical Liver Abscesses. Front Oncol 2022;12:723089. [DOI: 10.3389/fonc.2022.723089] [Reference Citation Analysis]
19 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
21 Lin Z, Yang S, Zhou Y, Hou Z, Li L, Meng M, Ge C, Zeng B, Lai J, Gao H, Zhao Y, Xie Y, He S, Tang W, Li R, Tan J, Wang W. OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis. Transl Oncol 2022;16:101331. [PMID: 34974280 DOI: 10.1016/j.tranon.2021.101331] [Reference Citation Analysis]
22 Chiang NJ, Hou YC, Tan KT, Tsai HW, Lin YJ, Yeh YC, Chen LT, Hou YF, Chen MH, Shan YS. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. Hepatol Int 2022. [PMID: 35780451 DOI: 10.1007/s12072-022-10346-3] [Reference Citation Analysis]
23 Qiu H, Liu C, Huang M, Shen S, Wang W. Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Manag Res 2021;13:5969-80. [PMID: 34377017 DOI: 10.2147/CMAR.S320380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Guo H, Qian Y, Yu Y, Bi Y, Jiao J, Jiang H, Yu C, Wu H, Shi Y, Kong X. An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Front Oncol 2022;12:791867. [DOI: 10.3389/fonc.2022.791867] [Reference Citation Analysis]
25 Liu J, Tian T, Liu X, Cui Z, Wang F. BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity. Journal of Immunology Research 2022;2022:1-20. [DOI: 10.1155/2022/6051092] [Reference Citation Analysis]
26 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 2022;29:551-64. [DOI: 10.3390/curroncol29020050] [Reference Citation Analysis]
28 Wang Y, Tian Y, Liu S, Wang Z, Xing Q. Prognostic value and immunological role of AXL gene in clear cell renal cell carcinoma associated with identifying LncRNA/RBP/AXL mRNA networks. Cancer Cell Int 2021;21:625. [PMID: 34838035 DOI: 10.1186/s12935-021-02322-y] [Reference Citation Analysis]
29 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Reference Citation Analysis]
30 Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, Mei J, Wei W, Guo R. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med 2022;54:803-11. [PMID: 35272564 DOI: 10.1080/07853890.2022.2048416] [Reference Citation Analysis]
31 Koonmee S, Sangkhamanon S, Intarawichian P, Aphivatanasiri C, Kunprom W, Sa-Ngiamwibool P, Balthaisong S, Phuyao C, Prajumwongs P, Alaghehbandan R, Thanee M. The Impact of Pre-analytical Quality Initiatives on Cholangiocarcinoma Diagnostics in Thailand. Front Public Health 2022;10:792847. [PMID: 35757604 DOI: 10.3389/fpubh.2022.792847] [Reference Citation Analysis]
32 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
33 Kim H, Kim H, Kim R, Jo H, Kim HR, Hong J, Park JO, Park YS, Kim ST. Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technol Cancer Res Treat 2021;20:15330338211062324. [PMID: 34855561 DOI: 10.1177/15330338211062324] [Reference Citation Analysis]
34 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs 2021;:1-7. [PMID: 34793275 DOI: 10.1080/13543784.2022.2008354] [Reference Citation Analysis]
36 Yi B, Zhao Z, Dong H, Yuan L, Wu Y, Xu Y, Jiang X, Sun C, Wu D, Xiao Y. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment. Front Immunol 2022;13:820566. [PMID: 35242133 DOI: 10.3389/fimmu.2022.820566] [Reference Citation Analysis]
37 Huang C, Wen Q, Chen J, Zhong H, Xiang X, Xiong J, Deng J. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma. Cancer Treatment and Research Communications 2022;31:100568. [DOI: 10.1016/j.ctarc.2022.100568] [Reference Citation Analysis]
38 Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Reference Citation Analysis]
39 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Uson Junior PLS, Araujo RL. Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World J Gastrointest Oncol 2022; 14(8): 1446-1455 [DOI: 10.4251/wjgo.v14.i8.1446] [Reference Citation Analysis]
41 Nan L, Wang C, Dai Y, Wang J, Bo X, Zhang S, Zhang D, Liu H, Wang Y. Cystic Duct Carcinoma: A New Classification System and the Clinicopathological Features of 62 Patients. Front Oncol 2021;11:696714. [PMID: 34178696 DOI: 10.3389/fonc.2021.696714] [Reference Citation Analysis]
42 Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y, Zhang X, Ruan J. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215853] [Reference Citation Analysis]
43 Zhang B, Li S, Liu ZY, Peiris KGK, Song LF, Liu MC, Luo P, Shang D, Bi W. Successful multimodality treatment of metastatic gallbladder cancer: A case report and review of literature. World J Clin Cases 2022; 10(12): 3856-3865 [DOI: 10.12998/wjcc.v10.i12.3856] [Reference Citation Analysis]
44 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Rev Gastroenterol Hepatol 2021;15:1241-3. [PMID: 34553646 DOI: 10.1080/17474124.2021.1984879] [Reference Citation Analysis]
45 Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol 2022;13:871262. [DOI: 10.3389/fphar.2022.871262] [Reference Citation Analysis]
46 Liu M, Huang L, Wu J, Zhang H, Ai W, Zhang R. Possible roles of Golgi protein-73 in liver diseases. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100720] [Reference Citation Analysis]
47 Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Front Public Health 2022;10:835914. [DOI: 10.3389/fpubh.2022.835914] [Reference Citation Analysis]
48 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Jiang Q, Huang J, Zhang B, Li X, Chen X, Cui B, Li S, Guo G. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:801909. [PMID: 35309350 DOI: 10.3389/fimmu.2022.801909] [Reference Citation Analysis]
50 Singh J, Shukla D, Gupta S, Shrivastav BR, Tiwari PK. Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic/prognostic prediction of GBC. Cancer Treat Res Commun 2021;28:100431. [PMID: 34333247 DOI: 10.1016/j.ctarc.2021.100431] [Reference Citation Analysis]
51 Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol 2022;6:e2200003. [PMID: 35772047 DOI: 10.1200/PO.22.00003] [Reference Citation Analysis]
52 Lawal B, Kuo YC, Tang SL, Liu FC, Wu ATH, Lin HY, Huang HS. Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration. Cells 2021;10:2873. [PMID: 34831096 DOI: 10.3390/cells10112873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]